Recombinant human neuregulin-1 (rhNRG-1) improves cardiac function in experimental heart failure models, but the underlying mechanism remains largely unknown. In this study, we evaluated whether rhNRG-1 could improve cardiac function via the cardiac myosin light chain kinase/myosin light chain 2 ventricular (cMLCK/MLC-2v) pathway in rats with myocardial infarction (MI).
Introduction
The ErbB family of receptor tyrosine kinases consists of four members, ErbB1, ErbB2, ErbB3, and ErbB4. Epidermal growth factor (EGF) binds with ErbB1, neuregulin (NRG) 1 and 2 with ErbB3 and ErbB4, and NRG 3 and 4 with ErbB4 dimers.
1 ErbB2 is incapable of binding with a ligand directly, but can form dimers with either ErbB3 or ErbB4 following NRG binding and receptor activation. ErbB2/ErbB4 activation is essential for normal cardiac development and maintenance of structural and functional integrity of the adult heart. 3 Recombinant human neuregulin-1 (rhNRG-1, part of NRG 1) is a 61-amino-acid peptide containing an EGF-like domain. Previously, we reported rhNRG-1 activates Erb2/4 heterodimerization, thus improving cardiac function and survival rate in animal models of ischaemic or viral cardiomyopathies. 4, 5 However, the underlying molecular mechanism remains to be verified. Myosin light chain kinases (MLCKs) belong to a family of genes encoding a number of serine/threonine kinases that are expressed in a tissue-specific manner. It was reported that the targeted deletion of either smooth or skeletal MLCK genes produced no significant effect on cardiomyocyte development or function. 6, 7 Recently, cardiac MLCK (cMLCK) was identified in regulation of phosphorylation of ventricular myosin light chain 2 (MLC-2v), sarcomere organization, and cardiomyocyte contraction. 8, 9 Phosphorylation of MLC-2v was found to play an important regulatory role in maintaining normal cardiac function in animals. 10, 11 In our previous independent study to investigate the mechanism of rhNRG-1-induced heart function improvement, interestingly, we found that rhNRG-1 up-regulated the expression of Neukinase, also called cMLCK, using the microarray technology (patent application no. USSN60/839388, 21 August 2006, GenBank: EU236721.1).
In this study, we investigated the changes of cMLCK/MLC-2v in rats with myocardial infarction (MI), induced by left anterior descending (LAD) coronary artery ligation, treated with rhNRG-1. In the cultured neonatal cardiomyocytes treated with or without rhNRG-1 and cMLCK RNA interference (RNAi), we examined cMLCK expressions, MLC-2v phosphorylation, and sarcomeric disarray, and we also assessed cardiac function in the rats with MI infected with the cMLCK gene.
Methods
[Supplementary Methods are available online.]
MI model
All the animal procedures, approved by the Animal Care and Use Committee of Shanghai City, China, conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) . Adult Wistar rats were anaesthetized with ketamine hydrochloric acid (100 mg/kg intraperitoneal), and the LAD was ligated as previously described. 4 Shamoperated animals were treated in a similar manner, except that the suture around the LAD was left untied. The infarcted animals were randomly divided into two groups 8 weeks later, based on the echocardiographic results before commencement of continuous intravenous infusion of rhNRG-1 (5 mg/kg/h; the b2a isoform produced in Escherichia coli 4 ) or vehicle 4 for 7 days at a delivery rate of 10 mL/h through osmotic pumps. 12 At the end of the treatment, echocardiography was repeated.
GeneChip w detection and real-time PCR
In the groups of vehicle-treated, rhNRG-1-treated and sham-operated rats, the total RNA was individually extracted from the non-infarcted fraction of the left ventricle (LV), with three independent samples being hybridized with nine GeneChip w Rat Genome 230 2.0 Arrays (Affymetrix, Santa Clara, CA, USA), respectively. In comparison, the selected and clustered candidate genes, with at least a 1.5-fold change in the level of expression, were implemented in GeneSpring 7.31 (Agilent, Santa Clara, CA, USA). The procedures were mainly performed as previously described. 13, 14 Real-time PCR was performed with the SYBR w Premix Ex Taq TM (Takara, Shiga, Japan) to confirm the results from the chip scanning according to the manufacturer's instructions.
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cMLCK-specific antibody preparation
A specific segment of cMLCK (nucletides 487-885) was cloned into a pGEX-2T expression vector (Pharmacia, Piscataway, NJ, USA), so that the desired antigen (GST-487) was expressed, purified, quantified, and injected with Freund's adjuvant (Sigma, St Louis, MO, USA) every 3 weeks to immunize the rabbits. High titres of the corresponding polyclonal anti-sera (rabbit anti-GST-487) were observed via ELISA, and were harvested after four injections. 18 
Immunoprecipitation and Western blotting
The tissue or the cell lysate was collected and quantified with the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Afterwards, an immunoprecipitation (IP) starter pack (Amersham Biosciences, Uppsala, Sweden) was employed according to the protocol; the Western blot was performed as previously described. 1 The LV non-infarcted fractions from the sham, MI, and rhNRG-1-treated groups were used to detect the changes of cMLCK and phosphorylated MLC-2v (MLC-2v-P) via IP and Western blot analysis.
Cardiomyocyte culture and IF
Primary cultures of neonatal cardiomyocytes were prepared as previously described, but with minor modifications. 19 -21 The isolated cells were harvested in two different ways: the purified cells as cardiomyocytes enriched by a discontinuous Percoll gradient (1.060 -1.086 g/mL) to observe the cction of cMLCK on sarcomeres; the unpurified cells as a mixture of cardiomyocytes, smooth muscle cells, and others, to define the distribution of cMLCK and smooth muscle MLCK (smMLCK). The enriched cardiomyocytes were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS); serum-free medium; serumfree medium supplemented with rhNRG-1 (10 nM); serum-free medium plus ML-7 (C 15 H 17 IN 2 O 2 S . HCl, an inhibitor for MLCKs; 10 mM; Sigma); and serum-free medium supplemented rhNRG-1 and ML-7. The cells were labelled with anti-a-actinin to quantify the extent of sarcomeric disarray 24 h later, and a total of 100 cardiomyocytes were counted in each group. The semi-quantitative morphology score of the myofibrils was defined on the fraction of the area occupied by the organized sarcomeres relative that to the total of the cells: ,one-third of cell area, poor; ≥one-third, but ,two-thirds, moderate; or ≥two-thirds, well.
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For IF, the cells or heart tissue slides were prepared, fixed, blocked, incubated with appropriate antibodies, and analysed by laser confocal microscopy (Leica, Germany). 23 
cMLCK RNAi
The target sites for RNAi were selected using online programs (http:// www.takara.com.cn). The RNAi sequences designated for cMLCK coding regions (nucleotides 156 -174) were designed and inserted into a commercially available lentiviral short hairpin RNA vector with a green fluorescent protein (GFP) construct incorporated to track siRNA expression (LVsh156-GFP). 24, 25 The lentiviral vector with a scrambled sequence was used as the control (LVsh -GFP). The purified cardiomyocytes, infected overnight with equal amounts of virus particles [titre, 1 × 10 8 inclusion forming units (ifu)/mL], were harvested 72 h later. Some were stained for a-actinin and analysis by laser confocal microscopy, and others were assessed by western blot to observe changes in the expression levels of cMLCK and MLC-2v protein.
Gene delivery method used in rats
We designed an independent study in order to observe cardiac function upon cMLCK gene transfer, in which the first surgery of LAD coronary artery ligation was performed in male Wistar rats as previously described, and the sham group was treated in a similar manner, except that the suture around the LAD coronary artery was left untied. Eight weeks later, the MI rats within a given range of ejection fraction (EF) values were randomized into three groups: MI -GFP, MI -cMLCK and MI-NRG. The MI-GFP group received the virus without cMLCK gene, the MI-cMLCK group received the virus containing rat cMLCK, and the MI-NRG group received rhNRG-1 and the virus without cMLCK gene. The sham group was planned to receive the virus without cMLCK. The adenoviruses containing rat cMLCK -GFP were constructed as previously described, 26 and the adenoviruses without cMLCK gene were used as a control. The adenoviruses were intramuscularly injected in the non-infarcted anterior area of the LV free wall using an Neuregulin-1 and cardiac myosin light chain kinase insulin syringe (29 gauge; BD Bioscience), 27, 28 and 50 mL adenovirus (1 × 10 10 ifu/mL) per site was injected at four sites in each heart during a second surgical procedure, which was followed by a 2 week recovery period before echocardiographic and haemodynamic assessment of ventricular function was performed.
Echocardiography, haemodynamics, and histomorphology
Echocardiography was performed on the rats anaesthetized with ketamine hydrochloride as described previously. 29 The left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), EF and fraction of shortening (FS) were assessed as measures of cardiac function. 3 Haemodynamic measurements were determined via micro-manometry (Power Lab System, Bella Vista, NSW, Australia) in rats anaesthetized with sodium pentobarbital (30 mg/kg intraperitoneally), 29 after which the heart was harvested and stained with Masson's trichrome for measurement of infarct size with a digital image analyser (Leica, Solms, Germany). The external and internal perimeters of the LV and the scar area were measured, and the ratio of scar and LV perimeters used to express the infarct size. 30 The expressions of cMLCK and phosphorylation of MLC-2v were detected via western blot and IP.
Statistical analysis
The data are presented as means + SEM and analysed by one-way ANOVA followed by Tukey's post hoc analysis, two-factor ANOVA (group and time), or Student's paired t-test (self control) as indicated; P , 0.05 was considered statistically significant. The relative percentage of the cells with the organized sarcomeres was analysed on using the non-parametric test followed by an independent t-test. The statistical analysis was performed with SPSS software (SPSS Inc., Chicago, IL, USA).
Results
Improved cardiac contractile function by rhNRG-1 (intravenous infusion) post-MI
Once the alteration in cardiac contractile function induced by LAD coronary artery ligation had stablized, the animals were randomized to receive either rhNRG-1 (5 mg/kg/h, intravenous infusion) or a corresponding volume of vehicle, continuously for 7 days via an osmotic mini-pump. The third group, the sham-operated animals, served as an additional control group. A baseline echocardiogram was performed before and at the end of the treatment to evaluate the cardiac function over the period, showing that the left ventricular dimensions increased, contractile function declined, and EF and FS values reduced in the vehicle-treated animals following LAD coronary artery ligation ( Figure 1 ). In contrast, the data in the rhNRG-1 group showed a statistically significant increase in EF and FS, but a decrease in LV diameter, all of which, however, were still far from the normal values. Figure 1 rhNRG-1 improved cardiac dimensions and performance post LAD coronary artery ligation based on echocardiography. Eight weeks after LAD coronary artery ligation, rats received no treatment (sham-operated group, n ¼ 10), vehicle (MI group, n ¼ 19), or rhNRG-1 (5 mg/kg/h, MI plus rhNRG-1 group, n ¼ 24) infused intravenously for 7 days. Cardiac performance was evaluated by echocardiography before and after the treatment. LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; EF, ejection fraction; FS, fractional shortening. **P , 0.01 rhNRG-1 vs. vehicle group.
GeneChip w Results
RNA samples were prepared from the non-infarcted regions of rhNRG-1-or vehicle-treated rats post-MI and from the corresponding regions of the sham-operated animals (n ¼ 3 in each group), followed by separate hybridization to GeneChip w Arrays. A total of 1950 genes, selected based on changes in gene expression of ≥1.5-fold in comparison with those of other groups (P , 0.05), were used as computational input for hierarchical clustering based on the pattern similarity of gene expression, 14 the results of which were displayed in a dendrogram, showing a higher degree of similarity in the sham-operated and rhNRG-1-treated MI rats compared with the vehicle-treated rats post-MI (Figure 2A) . The absolute data were normalized and further annotated (see Supplementary material online, Table S1 ; also available at the GEO website at GEO accession, GSE9263, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi). The genes were also grouped based on their biological contexts, such as signalling pathways, contractile and cytoskeletal components, metabolic pathways, calcium handling, etc. (see Supplementary material online, Table S2 ). We placed a focus on the genes related to cardiac muscle contraction, one of the most important cardiac functions, and found that the mRNA expression of myosin heavy polypeptide 6 (Myh6) and 7 (Myh7) decreased following the rhNRG-1 treatment.
In contrast, the cardiac myosin light chain kinase increased significantly, and this was therefore selected for further investigation in the present study.
Up-regulation of cMLCK expression and increase in phosphorylation of MLC-2v in MI rats treated with rhNRG-1
The mRNA of cMLCK was found to be down-regulated in the vehicletreated MI rats in comparison with the sham-operated animals, and significantly up-regulated in the rhNRG-1-treated MI animals. In contrast, smMLCK remained the same ( Figure 2B and C) . The change of cMLCK mRNA expression was further confirmed by real-time PCR ( Figure 3A) , and a similar change of cMLCK protein was also observed ( Figure 3B ). The possible change of MLC-2v, a well-known substrate of cMLCK, was then measured, and it was found that MLC-2v phosphorylation significantly decreased in the vehicle-treated MI hearts in comparison with the sham-operated hearts. Moreover, rhNRG-1 increased MLC-2v phosphorylation significantly in the hearts of rats with MI ( Figure 3B ; P , 0.01 vs. vehicle, n ¼ 5), whereas no change occurred in smMLCK protein expression in each group (Figure 3C) , consistent with the GeneChip w results.
Distribution of cMLCK
The cultured, unpurified cells were double stained with an anti-aactinin antibody, specific for cardiomyocytes, and an anti-cMLCK antibody, and showed a relationship between the cardiac structural protein a-actinin (red) and cMLCK (green) in the cardiomyocyte ( Figure 4A-C) . The co-expression of smooth muscle-specific a-actin (red) and smMLCK (green) was also evident in the unpurified cells double stained with an anti-smooth muscle a-actin (a-SMA) antibody and an anti-smMLCK antibody ( Figure 4D-F) . When double stained with an anti-smMLCK antibody (red) and an anti-cMLCK antibody (green), however, the labels were apparent in the different cellular types ( Figure 4G -I), with cMLCK being expressed exclusively in cardiomyocytes, whereas smMLCK was restricted to the smooth muscles. This observation was further confirmed in the frozen sections of normal myocardium by double staining; vascular smooth muscle cells were stained with anti-smMLCK (red), and cardiomyocytes were labelled with anti-cMLCK (green; Figure 4J -L). Neuregulin-1 and cardiac myosin light chain kinase 3.5 cMLCK-dependent effects of rhNRG-1 on sarcomere structure and organization Cultured in DMEM with 10% FBS (Figure 5Aa) , serum-free medium (Figure 5Ab) , serum-free medium supplemented with rhNRG-1 (Figure 5Ac) , serum-free medium plus ML-7 (Figure 5Ad) , or serum-free medium supplemented rhNRG-1 and ML-7 (Figure 5Ae) , the enriched neonatal cardiomyocytes were well organized by 93, 38, 72, 16, and 18%, respectively (Figure 5Af ). More such cells were observed in the medium containing 10% FBS, and in the serum-free medium with additional rhNRG-1. Those cultured in the serum-free medium with the addition of ML-7, and in serum-free media with both rhNRG-1 and ML-7, were found to be less organized than those in the serumfree medium (P , 0.01).
The serum-free medium did not support normal sarcomere structure (Figure 5Ab ), while rhNRG-1 was both necessary and sufficient to induce normal sarcomere architecture (Figure 5Ac) . The effect of rhNRG-1 on reorganization was inhibited by ML-7 (P , 0.01).
RNAi technology was used to further characterize the function of cMLCK. Three groups were established as follows: serum-free culture and LVsh-GFP; serum-free medium with rhNRG-1 (10 nM) and LVsh-GFP; and serum-free culture medium with rhNRG-1 and LVsh156-GFP. It was found that transfection efficiencies were 80% or higher in cardiomyocytes, as monitored by GFP expression. As expected, the results showed that serum-free media disrupted normal sarcomere structure (Figure 5Ba-c) , which could be reversed by rhNRG-1 stimulation (Figure 5Bd -f) . When cMLCK expression was inhibited by LVsh156 -GFP, the structural restoration induced by rhNRG-1 was disrupted (Figure 5Bg -i) , consistent with the MLCK inhibition data (Figure 5Ad and e) .
The expression of cMLCK and phosphorylation of MLC-2v were decreased by cMLCK RNAi
Lysates of the cultured cardiomyocytes (transferred with LVsh-GFP or LVsh156 -GFP) were collected and detected by western blot to confirm a decrease in the expression of cMLCK. RNAi routinely resulted in an 80% decrease in both cMLCK protein expression and MLC-2v phosphorylation, as assessed by western blot analysis (Figure 5Ca, lanes D and E) . The addition of rhNRG-1 failed to prevent the reduction in levels of cMLCK and MLC-2v-P caused by RNAi (Figure 5Ca , lane E), confirming that the RNAi knocked down cMLCK to an extent greater than the degree to which rhNRG-1 induced cMLCK expression. Although the same levels of cMLCK protein expression were detected in LVsh -GFP transfected cells (Figure 5Ca, lanes A, B, and C) , less MLC-2v-P was observed in serumfree cell culture (Figure 5Ca, lane B) . Conversely, phosphorylation of MLC-2v was enhanced by rhNRG-1 stimulation (Figure 5Ca, lane C) . Semi-quantitative analysis of cMLCK expression and phosphorylation of MLC-2v were observed (Figure 5Cb ).
Cardiac function was improved by cMLCK gene transfer
Adenovirus with or without the coding region of rat cMLCK was injected into the non-infarcted area of the LV of the rats post-MI, and cardiac function was assessed by echocardiography and micromanometry 2 weeks later. EF and FS in the MI-cMLCK group were found to be significantly higher than those in MI-GFP group, but lower than those in MI-NRG group, whereas LVESD was reduced more significantly in the MI-cMLCK group than in the MI-GFP group, and far more than in the MI-NRG group. Compared with pretreatment measurements, EF and FS decreased significantly in the MI-GFP group and increased in the MI-cMLCK and MI -NRG groups, whereas LVESD decreased in the MI -NRG group and increased in the MI-GFP group, but showed no significant difference in the MIcMLCK group. All these measures were still far from the normal values ( Table 1) . The +dP/dt max and LVSP increased significantly in the MI-cMLCK and MI -NRG groups in comparison with the MI -GFP group, whereas -dP/dt max and LVEDP decreased significantly in the MI-NRG group in comparison with the MI-GFP and MIcMLCK groups (Figure 6A-D) . A successful virus transfer in the cardiac muscle was confirmed by the cMLCK expression and MLC-2v phosphorylation ( Figure 6E and F ) . The infarct sizes were not significantly different among the three MI groups ( Figure 6G) . 
Discussion
We have previously reported that rhNRG-1 (intravenous bolus) improves cardiac function in several experimental models of heart failure. 4 In the MI model of the present study, we demonstrated that continuous infusions of rhNRG-1 over 7 days significantly attenuated the dysfunction in all parameters of left ventricular function. EF and FS increased by 62.5 and 75.1%, respectively, which was accompanied by an 18.8 and 9.1% decrease in LVESD and LVEDD, respectively, in animals treated with rhNRG-1 when compared with vehicle-treated rats, although such measures were still far from the normal values. In comparison with the previous data based on the same model that rhNRG-1 (10 mg/kg, intravenous bolus, once daily for 10 days) increased EF and FS by 45.9 and 62.2%, respectively, and decreased LVESD and LVEDD by 17.4 and 8.5%, respectively, 4 the results of the present study demonstrated a better and more stable cardiac functional improvement than that of animals treated with intravenou injections once a day for 10 days, suggesting that a sustained activation of NRG-1/ErbB signalling could contribute to the biological effect.
As indicated by the GeneChip w results, the expressions of many genes were altered post rhNRG-1 treatment, including that of Figure 4 cMLCK was expressed specifically in cardiomyocytes. Cultured, unpurified neonatal rat heart cells (see Methods) were double stained with anti-a-actinin and anti-cMLCK antibodies to show cardiac a-actinin (A), cMLCK (B), and both (C). The same cells were double labelled with anti-smooth muscle a-actin and anti-smMLCK antibodies to show smooth muscle a-actin (D), smMLCK (E), and both (F). The same cells were double stained with anti-smMLCK and cMLCK antibodies to show smooth muscle (G), cardiac muscle (H), and both cell types (I). The rat heart frozen sections were double stained with anti-smMLCK and cMLCK antibodies to show smooth muscle (J), cardiac muscle (K), and both cell types (L). White scale bar (I) represents 20 mm.
Neuregulin-1 and cardiac myosin light chain kinase cardiac ryanodine receptor 2, which could play a key role in investigation of the mechanism of action of rhNRG-1. In the present study, the previously reported changes 31 were also observed in ubiquitin, cyclin D1, heat shock protein 90, the Grb family, Ras, phosphatidylinositol 3-kinase catalytic a polypeptide, the bcl-2 family, and genes involved in energy metabolism. However, the chip results of Myh 6 and 7 were found to be different from those observed in the previous literature.
In the present study, rhNRG-1 significantly increased cMLCK expression and MLC-2v phosphorylation in the hearts of the rats post-MI, and rhNRG-1 induced sarcomere reorganization of cardiomyocytes cultured in serum-free medium mediated via cMLCK -MLC-2v signalling. The cMLCK RNAi could attenuate the beneficial effect of rhNRG-1 on the reorganization. Furthermore, cardiac function was significantly improved in the cMLCK transgenic animals. It would be more conclusive to analyse sarcomeres in cardiomyocytes isolated from the treated animals by immunohistochemical or microscopical methods.
It could be concluded from the results from such cardiomyocytes that the function of cMLCK in rhNRG-1-mediated actions could be improved in vitro. However, the study showed no data suggesting changes in survival following this treatment, and there were fairly modest functional changes in vivo. Such modest improvement, however, could suggest that further optimization of the dose or delivery method could enhance the degree of therapeutic effect. The molecular and mechanistic explanations for the mechanism by which rhNRG-1 increased cMLCK expression and induced phosphorylation of MLC-2v are under investigation in our other related studies. However, there are several possible explanations describing the close association between functional improvement and up-regulation of the activation of the cMLCK -MLC-2v pathway by rhNRG-1 in the hearts of rats post-MI.
First, our in vitro results demonstrated that the up-regulated expression of cMLCK protein by rhNRG-1 promotes sarcomere reassembly, which might enhance contractility of the failing heart. Previous reports have demonstrated that increased cMLCK expression significantly increases cell motion, +dL/dT (contraction), and 2dL/dT (relaxation) in cardiomyocytes and that up-regulation of cMLCK could promote sarcomere reassembly and enhance contractility of the failing heart, 8, 9 suggesting that the up-regulation of cMLCK could be a potential therapeutic modality in patients with chronic heart failure. Secondly, increased MLC-2v phosphorylation by rhNRG-1 could improve cardiac contractile function in rats post-MI. This is consistent with findings that atrial hypertrophy and dilatation with structural abnormalities, such as severe tricuspid valve insufficiency in transgenic mice, were induced by mutating three serines in MLC-2v to alanines, potential phosphorylation sites, which suggests that phosphorylation of MLC-2v might play a critical role in maintaining normal cardiac muscle integrity and function. 32 It was found that activation of MLCK in cardiomyocytes was necessary and sufficient for sarcomere organization in response to the hypertrophic agonist angiotensin II when rabbit skeletal MLCK was transferred into cardiomyocytes. Moreover, the constitutive activation of MLCK induced sarcomere assembly and organization without a concomitant increase in size or enhanced atrial natriuretic factor expression, while the inhibition of MLCK abrogated agonist-induced sarcomere assembly and organization, and the time course of angiotensin II-induced accumulation of phosphorylated MLC-2v closely paralleled that of the angiotensin IIinduced sarcomere organization.
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In addition, the present results in combination with those published previously demonstrated that the action of cMLCK on phosphorylated MLC-2v mediated normal assembly and organization of the sarcomere, which is consistent with the report that MLC-2v functions as an essential component of thick myofilament assembly and contractility of the heart. 33 Recently, the protein expression of cMLCK has been found to be lower than that of sham-treated rats 3 weeks after MI, 9 but the up-regulation of cMLCK was observed 4 weeks after the onset of MI. 8 In the present study, both the mRNA and the protein expression of cMLCK declined 8 weeks after the onset of MI. The variability in cMLCK expression might be ascribed to the temporal differences in the stage of heart failure, e.g. compensation vs. accelerated decompensation. Nevertheless, the same conclusion was achieved; that the up-regulation of cMLCK could promote sarcomere reassembly and enhance contractility of the failing heart. In the present study, the fact that cMLCK gene therapy was not as effective as rhNRG delivery could arise from both local injection-site overexpression of cMLCK vs. the systemic cardiac-wide exposure to rhNRG-1 delivered through a mini-pump, and the potentially detrimental effect on the inflammatory response of the delivery of adenovirus. Furthermore, it is likely that rhNRG-1 presented other pathways through which it could regulate the function of the heart apart from cMLCK, such as NRG-1 reducing doxorubicin-induced down-regulation of sarcoplasmic reticulum Ca 2+ ATPase, attenuating alterations of contraction and calcium transients in cardiomyocytes, and up-regulating glutathione reductase. Neuregulin-1 and cardiac myosin light chain kinase The data presented in this study suggest that rhNRG-1-induced overexpression, and therefore activation, of cMLCK could serve as a potential therapeutic target for heart failure. Furthermore, the overexpression of cMLCK alone in heart failure improved cardiac function, which could be a specific target for a therapy for heart failure. Generally, enhanced constriction alone would happen with metabolic overload. We have previously found that oxygen consumption is not increased in rhNRG-1-treated animals with heart failure, indicating that no extra metabolic burden occurs. Moreover, rhNRG-1 treatment in animals with different models of heart failure significantly prolongs the survival rate, 4 an important end-point of heart failure. Therefore, the up-regulation of cMLCK via rhNRG-1 treatment could benefit cardiac function for a long time, without an extra load.
In conclusion, our data showed that cMLCK is a downstream effector of rhNRG-1 involved in rhNRG-1-induced cardiac function improvement, and that myocardial cMLCK up-regulation could improve cardiac function in rats post-MI.
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